Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
about
The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedureAdenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism.The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonistsDifferential effects of selective adenosine antagonists on the effort-related impairments induced by dopamine D1 and D2 antagonism.Systemic administration of the adenosine A(2A) agonist CGS 21680 induces sedation at doses that suppress lever pressing and food intakeDopamine/adenosine interactions involved in effort-related aspects of food motivationDopamine, behavioral economics, and effort.Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum.mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism.Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.Intra-accumbens injections of the adenosine A2A agonist CGS 21680 affect effort-related choice behavior in rats.
P2860
Q24607362-C0B24791-7200-42B5-BBE4-B54899A714D0Q30482913-6627C16C-24C4-43B7-AC31-3CC55120C60EQ33591276-7DEF7AD5-A112-41B6-89D5-42A681013207Q33591302-1E903AD0-5E01-4F1D-864D-82A7CF0A397CQ33872174-0667BAFF-E47A-4EBA-9391-E61344FCA166Q35706890-F5583E90-5DBB-4F78-B185-53783FC42A15Q37172329-EAC53AF4-16C5-4603-B64F-3849577B5172Q37563696-8299AEA1-2287-4F77-97B0-64AAE57688C2Q37614233-D295CC9D-6313-47B6-A7C8-D1198C94AA9AQ37902895-6D643D6B-E297-4D9A-A697-D4E624B8A846Q37979784-45E08882-413E-48AE-A3D7-B6C38D3E9406Q38169996-A8590ABC-44C0-46F1-B82A-E22D9AA5D124Q38323124-266E6F9E-E501-46CC-977F-969EA8E0DCA2Q38660240-8D861DD2-A850-492E-AF27-EB7EE2E8CF3BQ39008496-759A03E3-37E5-4FA2-88F2-AEC1F9BA1AA7Q39432789-21102CA3-8ACC-45FC-B387-1EF2549B8968Q42135362-68F3384F-F2B4-4212-8653-738065F5C099Q43180394-8F1C9342-177B-4676-A49B-3E27AF8D1C8A
P2860
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Interaction between dopamine a ...... atment of Parkinson's disease.
@en
Interaction between dopamine a ...... atment of Parkinson's disease.
@nl
type
label
Interaction between dopamine a ...... atment of Parkinson's disease.
@en
Interaction between dopamine a ...... atment of Parkinson's disease.
@nl
prefLabel
Interaction between dopamine a ...... atment of Parkinson's disease.
@en
Interaction between dopamine a ...... atment of Parkinson's disease.
@nl
P356
P1476
Interaction between dopamine a ...... eatment of Parkinson's disease
@en
P2093
P2888
P356
10.1007/S100720170052
P577
2001-02-01T00:00:00Z